Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela, R. Jake Jacobs*, Oscar Arteaga, Maria S. Navarrete, Allen S. Meyerhoff, Bruce L. Innis

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

43 Citas (Scopus)

Resumen

Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

Idioma originalInglés
Páginas (desde-hasta)4110-4119
Número de páginas10
PublicaciónVaccine
Volumen23
N.º32
DOI
EstadoPublicada - 14 jul. 2005

Huella

Profundice en los temas de investigación de 'Cost-effectiveness of universal childhood hepatitis A vaccination in Chile'. En conjunto forman una huella única.

Citar esto